Protocols
13 protocol(s) meet the specified criteria
Disease Site: Lip, Oral Cavity and Pharynx
Protocol No.TitleStatus
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
BP29889AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY, PART I) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN PATIENTS WITH METASTATIC SOLID TUMORSOpen
C-145-03A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckOpen
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
LCCC1430Phase Ib trial of Dose-escalating AZD1775 in Combination with Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)Open
LCCC1612P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers Open
LCCC1621Multimodality Therapy with Induction Carboplatin/nab-Paclitaxel/Durvalumab (MEDI4736) Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Open
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NBTXR3-1100A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY SABR FOR PATIENTS WITH ADVANCED HNSCC OR NSCLC TREATED WITH AN ANTI-PD1 ANTIBODYOpen
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland TumorsOpen